Karlan BY - Search Results

1

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Monk BJ, et al. Among authors: karlan by. Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18. Gynecol Oncol. 2016. PMID: 27546885 Clinical Trial.

2

Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation.

Karlan BY, Baldwin RL, Cirisano FD, Mamula PW, Jones J, Lagasse LD. Karlan BY, et al. Gynecol Oncol. 1995 Oct;59(1):67-74. doi: 10.1006/gyno.1995.1269. Gynecol Oncol. 1995. PMID: 7557618

3

Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.

Cane P, Azen C, Lopez E, Platt LD, Karlan BY. Cane P, et al. Among authors: karlan by. Gynecol Oncol. 1995 May;57(2):240-5. doi: 10.1006/gyno.1995.1133. Gynecol Oncol. 1995. PMID: 7729742

4

Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.

Jones J, Lagasse LD, Karlan BY. Jones J, et al. Among authors: karlan by. Gynecol Oncol. 1994 Dec;55(3 Pt 1):421-6. doi: 10.1006/gyno.1994.1316. Gynecol Oncol. 1994. PMID: 7835782

5

The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.

Karlan BY, Platt LD. Karlan BY, et al. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S28-33. doi: 10.1006/gyno.1994.1337. Gynecol Oncol. 1994. PMID: 7835806 Review.

6

Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.

Karlan BY, Jones J, Slamon DJ, Lagasse LD. Karlan BY, et al. Gynecol Oncol. 1994 Apr;53(1):70-7. doi: 10.1006/gyno.1994.1090. Gynecol Oncol. 1994. PMID: 7909787

7

The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery.

Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse LD, Berek JS. Farias-Eisner R, et al. Gynecol Oncol. 1994 Oct;55(1):108-10. doi: 10.1006/gyno.1994.1257. Gynecol Oncol. 1994. PMID: 7959250

8

Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.

McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. McGonigle KF, et al. Among authors: karlan by. Gynecol Oncol. 1994 Oct;55(1):126-32. doi: 10.1006/gyno.1994.1261. Gynecol Oncol. 1994. PMID: 7959253

9

Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.

Karlan BY, Hawkins R, Hoh C, Lee M, Tse N, Cane P, Glaspy J. Karlan BY, et al. Gynecol Oncol. 1993 Nov;51(2):175-81. doi: 10.1006/gyno.1993.1268. Gynecol Oncol. 1993. PMID: 8276290

10

The etiology and management of diarrhea in the gynecologic oncology patient.

Cirisano FD, Greenspoon JS, Stenson R, Farias-Eisner R, Karlan BY, Lagasse LD. Cirisano FD, et al. Among authors: karlan by. Gynecol Oncol. 1993 Jul;50(1):45-8. doi: 10.1006/gyno.1993.1162. Gynecol Oncol. 1993. PMID: 8349164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

520 results

Search Page

Filters